Kymera Therapeutics Inc (KYMR : NASDAQ)
Common Stock
$108.35
USD
+2.37 (2.24%)
Last updated: 2026-10-07
Follow KYMR
KYMR
Kymera Therapeutics Inc
WealthAwesomePerformance
1 Day
+2.24%
1 Week
-3.08%
1 Month
-7.70%
YTD
+20.52%
Key Statistics
Market Cap
$8.72B
52W High
$130.05
52W Low
$55.26
P/E Ratio
-
50 Day MA
$114.46
200 Day MA
$93.16
Beta
1.98
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/7/2026 | $104.58 | $108.68 | $103.45 | $108.35 | $108.35 | 1,166,284 |
| 10/6/2026 | $111.03 | $111.04 | $101.75 | $105.98 | $105.98 | 957,653 |
| 10/5/2026 | $108.38 | $109.92 | $103.33 | $109.85 | $109.85 | 729,511 |
| 10/2/2026 | $111.23 | $111.23 | $106.53 | $107.39 | $107.39 | 870,200 |
| 10/1/2026 | $111.79 | $116.20 | $109.41 | $110.12 | $110.12 | 1,051,066 |
| 9/30/2026 | $110.74 | $115.69 | $108.03 | $111.79 | $111.79 | 1,014,155 |
| 9/29/2026 | $110.54 | $111.92 | $108.97 | $110.51 | $110.51 | 447,205 |
| 9/28/2026 | $111.95 | $113.59 | $110.51 | $112.00 | $112.00 | 723,650 |
| 9/25/2026 | $115.99 | $116.20 | $111.42 | $111.95 | $111.95 | 698,400 |
| 9/24/2026 | $115.28 | $116.41 | $111.36 | $115.81 | $115.81 | 837,316 |
Analyst Price Targets
Based on 23 analysts covering KYMR · as of Oct 6, 2026
Wall Street analysts forecast KYMR stock price to rise 28.6% over the next 12 months.
Consensus
Strong Buy4.65 / 5.00
Avg. Target
US$139.32
+28.6% Upside
Previously US$138.64 on Oct 5, 2026
Current Price
US$108.35
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on KYMR's historical volatility
30-Day Vol
33.1%
Annualized
90-Day Vol
53.1%
Annualized
Trend (90d)
-14.2%
Annualized drift
90d Mean
US$102.99
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$106.53 | US$95.03 – US$119.42 |
| 60 trading days | US$104.74 | US$89.12 – US$123.11 |
| 90 trading days | US$102.99 | US$84.50 – US$125.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Financials
- Revenue (TTM)
- $105.00M
- EBITDA
- $-339.89M
- Profit Margin
- -285.33%
- ROE (TTM)
- -24.15%
- EPS (Diluted)
- -3.25
- Book Value
- 18.23
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About KYMR.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GLE | Global Engine Group Holding Limited Ordinary Shares | $4.00 | +877.02% |
| SXTC | China SXT Pharmaceuticals Inc | $2.83 | +126.40% |
| PFAI | Pinnacle Food Group Limited Class A Common Shares | $5.07 | +116.67% |
| CHARR | Charlton Aria Acquisition Corporation Rights | $0.18 | +80.00% |
| SBFM | Sunshine Biopharma Inc | $0.70 | +75.92% |
| BIYA | Baiya International Group Inc. Ordinary Shares | $2.30 | +68.50% |
| FEED | ENvue Medical Inc. | $0.43 | +50.84% |
| QETAR | Quetta Acquisition Corporation Right | $0.72 | +47.94% |
KYMR.US news timeline
1 article covering KYMR.US, most recent first
Latest